Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pan Tong

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Cancer Research|May 2, 2019
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in <i>KRAS</i>-Mutant Lung AdenocarcinomaAna Galan-Cobo, Piyada Sitthideatphaiboon, Xiao Qu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
Molecular Cancer Research : MCR|October 16, 2021
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-AdoAna Galan-Cobo, Christine M Stellrecht, Emrullah Yilmaz, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Oncotarget|March 28, 2018
Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancerDaniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2015
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI VandetanibMonique B Nilsson, Uma Giri, Jayanthi Gudikote, et al.
Cancer Research|May 2, 2019
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in <i>KRAS</i>-Mutant Lung AdenocarcinomaAna Galan-Cobo, Piyada Sitthideatphaiboon, Xiao Qu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2015
Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung CancerRenata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, et al.
Cancer Research|May 12, 2017
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or OlaparibTriparna Sen, Pan Tong, C Allison Stewart, et al.
Journal of the National Cancer Institute|April 5, 2017
Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung CancerMasanori Kawakami, Lisa Maria Mustachio, Jaime Rodriguez-Canales, et al.
Science Translational Medicine|March 15, 2019
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanismDavid H Peng, Samrat T Kundu, Jared J Fradette, et al.
Molecular Cancer Research : MCR|October 16, 2021
Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-AdoAna Galan-Cobo, Christine M Stellrecht, Emrullah Yilmaz, et al.
Oncotarget|November 2, 2017
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapiesRobert J Cardnell, Lerong Li, Triparna Sen, et al.
Science Translational Medicine|September 4, 2020
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint componentsMonique B Nilsson, Huiying Sun, Jacqulyne Robichaux, et al.
Pageof 6